Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
-20.0%
$0.00
$0.00
$0.06
$8K0.7710,980 shs4,282 shs
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
$0.00
$0.00
$0.00
$10KN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
$0.01
$13K-0.292,056 shsN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
$0.00
$0.00
$0.05
$4K1.94N/AN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-20.00%+33.33%-20.00%-84.00%-20.00%
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
0.00%0.00%0.00%0.00%0.00%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00%0.00%0.00%0.00%-85.71%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/AN/AN/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
0.00
N/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
$10K0.00N/AN/AN/ANaN
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/A6/30/2025 (Estimated)
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
-$5.16MN/A0.00N/AN/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/A0.00N/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
N/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
N/A

Insider Ownership

CompanyInsider Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
10.30%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
Global WholeHealth Partners Co. stock logo
GWHP
Global WholeHealth Partners
6143.88 million129.07 millionNot Optionable
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
942.08 million39.94 millionNot Optionable
Sophiris Bio, Inc. stock logo
SPHS
Sophiris Bio
635.55 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0004 0.00 (-20.00%)
As of 05/23/2025 09:54 AM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Global WholeHealth Partners stock logo

Global WholeHealth Partners OTCMKTS:GWHP

Global WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0003 0.00 (0.00%)
As of 05/22/2025

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Sophiris Bio stock logo

Sophiris Bio OTCMKTS:SPHS

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.